Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexrazoxane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 3/20 | 0.96 |
| ▸ | TOP2B known ✓ | Q02880 | 3/20 | 0.96 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.96 |
| ▸ | LMNA | P02545 | 1/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Razoxane SCHEMBL27174203 | 1.00 | TOP2A (0.96) | TOP2ATOP2BPTGS1LMNAALDH1A1 | |
| Dexrazoxane SCHEMBL18400 | 0.98 | TOP2A (1.00) | TOP2ATOP2BPTGS1LMNAALDH1A1 | |
| Razoxane SCHEMBL9089 | 0.98 | TOP2A (1.00) | TOP2ATOP2BPTGS1LMNAALDH1A1 | |
| Dexrazoxane SCHEMBL1586271 | 0.98 | TOP2A (1.00) | TOP2ATOP2BPTGS1LMNAALDH1A1 | |
| Razoxane SCHEMBL3339694 | 0.98 | TOP2A (1.00) | TOP2ATOP2BPTGS1LMNAALDH1A1 | |
| Razoxane SCHEMBL27748349 | 0.96 | TOP2A (0.96) | TOP2ATOP2BPTGS1LMNAALDH1A1 | |
| Dexrazoxane SCHEMBL18189 | 0.94 | TOP2A (0.93) | TOP2ATOP2BPTGS1LMNAALDH1A1 | |
| Dexrazoxane SCHEMBL27918475 | 0.94 | TOP2A (0.93) | TOP2ATOP2BPTGS1LMNAALDH1A1 | |
| Dexrazoxane SCHEMBL28086609 | 0.93 | TOP2A (0.89) | TOP2ATOP2BPTGS1LMNAALDH1A1 | |
| Dexrazoxane SCHEMBL5488431 | 0.90 | TOP2A (0.83) | TOP2ATOP2BPTGS1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2152 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132141-A1 | PROTEIN PHOSPHATASE 2A ACTIVATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-14 | — | — | US | claimed |
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| US-20250275946-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2025-09-04 | — | — | US | claimed |
| US-20250242046-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | MALCOLM THOMAS (US) | 2025-07-31 | — | — | US | claimed |
| US-20250232860-A1 | SMART DOSING FOR CANCER THERAPY | OPTIMDOSING LLC (US) | 2025-07-17 | — | — | US | claimed |
| US-12300370-B2 | Smart dosing for cancer therapy | OptimDosing, LLC (US) | 2025-05-13 | — | — | US | claimed |
| EP-4532024-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | Malcolm, Thomas (US) | 2025-04-09 | — | — | EP | claimed |
| CN-119677539-A | Combination therapy for modulating lipid production | 俄亥俄州创新基金会 | 2025-03-21 | — | — | CN | claimed |
| EP-4489865-A2 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | Ohio State Innovation Foundation (US) | 2025-01-15 | — | — | EP | claimed |
| WO-2024231899-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-11-14 | — | — | WO | claimed |
| EP-2310049-A1 | PROSTAGLANDIN E2 BINDING PROTEINS AND USES THEREOF | Abbott Laboratories (US) | 2011-04-20 | — | — | EP | claimed |
| US-20100040537-A1 | antibodies that are wild-type, chimeric, CDR grafted and humanized; disease or disorder in which prostaglandin E2 activity is detrimental, such as cancer, atuoimmune diseases, inflammatory diseases | ABBOTT LABORATORIES (US) | 2010-02-18 | — | — | US | claimed |
| WO-2010006059-A1 | PROSTAGLANDIN E2 BINDING PROTEINS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-01-14 | — | — | WO | claimed |
| WO-2008116165-A9 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | NEXT SAFETY INC (US) | 2009-06-11 | — | — | WO | claimed |
| WO-2008116165-A2 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | NEXT SAFETY, INC. (US) | 2008-09-25 | — | — | WO | claimed |
| US-20080066741-A1 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | HUNTER, CHARLES ERIC | 2008-03-20 | — | — | US | claimed |
| US-6693100-B1 | USING DEXRAZOXANE | CYATHUS EXQUIERE PHARMAFORSCHUNGS GMBH (AT) | 2004-02-17 | — | — | US | claimed |
| CN-1378451-A | Pharmaceuticla ocmpositions for treating psoriasis | CYATHUS EXQUIRERE PHARMAFORSCH (AT) | 2002-11-06 | — | — | CN | claimed |
| EP-1214073-A2 | USE OF DEXRAZOXANE FOR TREATING PSORIASIS | Cyathus Exquirere Pharmaforschungs GmbH (AT) | 2002-06-19 | — | — | EP | claimed |
| WO-2001019358-A2 | USE DEXRAZOXANE FOR TREATING PSORIASIS | CYATHUS EXQUIRERE PHARMAFORSCHUNGS GMBH (AT) | 2001-03-22 | — | — | WO | claimed |